BBA
AGN

Braun-Bostich & Associates’s Allergan plc AGN Stock Holding History

Braun-Bostich & Associates’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50
Closed -$9K – 336
2020
Q1 		$9K Hold
50
– – 0.01% 221
2019
Q4 		$10K Buy
+50
New +$9.02K 0.01% 246
2019
Q3 		– Sell
-50
Closed -$8K – 327
2019
Q2 		$8K Sell
50
-55
-52% -$7.62K 0.01% 276
2019
Q1 		$15K Sell
105
-96
-48% -$13.9K 0.02% 252
2018
Q4 		$27K Buy
201
+50
+33% +$8.2K 0.03% 206
2018
Q3 		$29K Buy
+151
New +$27.7K 0.03% 210
2018
Q2 		– Sell
-2,796
Closed -$471K – 334
2018
Q1 		$471K Buy
2,796
+601
+27% +$101K 0.41% 79
2017
Q4 		$359K Buy
+2,195
New +$394K 0.3% 93

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Braun-Bostich & Associates's AGN Position: Q2 2020 in Review

Braun-Bostich & Associates sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 50 shares — an estimated $9K sold.

Braun-Bostich & Associates first reported a position in AGN in Q4 2017 and held it in 8 quarters. The position peaked at $471K in Q1 2018. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • Braun-Bostich & Associates reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • Braun-Bostich & Associates sold 50 Allergan plc shares in Q2 2020, an estimated $9K.
  • Braun-Bostich & Associates first reported a position in Allergan plc in Q4 2017 and held it in 8 quarters.
  • Braun-Bostich & Associates's Allergan plc position peaked at $471K in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on Braun-Bostich & Associates's 13F filing for Q2 2020, filed 13 Aug 2020.